# Media Release

19 November 2026

# Results of Annual General Meeting

**Syntara Limited (ASX: SNT)**

In accordance with ASX Listing Rule 3.13.2, the results of the Company's Annual General Meeting (AGM) held on 19 November 2026 are set out in the attached document.

Except for Resolution 5 Approval of an Additional 10% Placement Capacity, all resolutions considered at the AGM were passed by poll.

#ENDS#

**About Syntara**

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

**SOURCE:**
Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

**AUTHORISED FOR RELEASE TO ASX BY:**
Syntara Limited Disclosure Committee.

**CONTACT:**

**Syntara investor / media relations:**
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

**JOIN THE SYNTARA MAILING LIST HERE**

**Syntara Limited**
**Annual General Meeting**
**Thursday, 19 November 2026**
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Resolution Result | If s250U applies |
|---|---|---|---|---|---|---|---|---|---|---|
| **Resolution** | **Resolution Type** | **For** | **Against** | **Proxy's Discretion** | **Abstain** | **For** | **Against** | **Abstain*** | **Carried / Not Carried** | |
| 1. Adoption of the remuneration report | Ordinary | 422,742,100<br>97.02% | 11,217,466<br>2.57% | 1,799,592<br>0.41% | 5,947,123 | 424,541,692<br>97.43% | 11,217,466<br>2.57% | 5,947,123 | Carried | No |
| 2. Re-election of Dr Simon Green as a Non-Executive Director | Ordinary | 485,574,998<br>98.62% | 5,359,575<br>1.09% | 1,430,645<br>0.29% | 12,665,934 | 487,005,643<br>98.91% | 5,359,575<br>1.09% | 12,665,934 | Carried | N/A |
| 3. Approval of the Annual Grant of 11,041,099 Performance Rights to Mr Gary Phillips | Ordinary | 432,466,964<br>85.66% | 70,861,808<br>14.04% | 1,500,645<br>0.30% | 201,735 | 433,967,609<br>85.96% | 70,861,808<br>14.04% | 201,735 | Carried | N/A |
| 4. Approval of the Grant of 3,087,108 Performance Rights to Mr Gary Phillips in lieu of Cash Salary and Superannuation | Ordinary | 479,085,787<br>94.88% | 24,322,985<br>4.82% | 1,500,645<br>0.30% | 121,735 | 480,586,432<br>95.18% | 24,322,985<br>4.82% | 121,735 | Carried | N/A |
| 5. Approval of an Additional 10% Placement Capacity (Special Resolution) | Special | 132,260,490<br>26.22% | 370,544,515<br>73.48% | 1,528,145<br>0.30% | 698,002 | 133,788,635<br>26.53% | 370,544,515<br>73.47% | 698,002 | Not Carried | N/A |
| 6. Reinstatement of proportional takeover provisions in the constitution (Special Resolution) | Special | 494,442,436<br>98.18% | 7,321,941<br>1.45% | 1,888,592<br>0.37% | 1,378,183 | 496,331,028<br>98.55% | 7,321,941<br>1.45% | 1,378,183 | Carried | N/A |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.